{"id":402380,"date":"2020-12-17T16:33:30","date_gmt":"2020-12-17T21:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=402380"},"modified":"2020-12-17T16:33:30","modified_gmt":"2020-12-17T21:33:30","slug":"hikma-launches-generic-advair-diskus-following-fda-approval","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hikma-launches-generic-advair-diskus-following-fda-approval\/","title":{"rendered":"Hikma launches generic Advair Diskus\u00ae following FDA approval"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LONDON<\/span>, Dec. 17, 2020<\/span> \/PRNewswire\/ —\u00a0Hikma Pharmaceuticals PLC\u00a0(Hikma),\u00a0the multinational pharmaceutical company, announces it has received FDA approval for and launched its generic version of GlaxoSmithKline’s Advair Diskus\u00ae1<\/sup> (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg\/50mcg and 250mcg\/50mcg doses in the US. <\/p>\n

\n

\n
\n \"(PRNewsfoto\/Hikma
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Hikma worked with Vectura Group, a UK based provider of innovative inhaler drug delivery solutions, to develop the proprietary dry powder inhaler and formulation technology. <\/p>\n

According to IQVIA, US sales of Fluticasone Propionate and Salmeterol Inhalation Powder USP, 100mcg\/50mcg and 250mcg\/50mcg, were approximately $2 billion<\/span> in the 12 months ending September 2020<\/span>.<\/p>\n

\n Siggi Olafsson<\/span>, Chief Executive Officer of Hikma, said “The approval of our generic version of Advair Diskus\u00ae <\/sup>marks\u00a0an important milestone in our strategy to develop more complex respiratory products.\u00a0 Through the unwavering dedication of our employees and close collaboration with the Vectura team, we have developed a high quality and substitutable generic product for Advair Diskus\u00ae <\/sup>that will improve availability of this critical medicine. We\u00a0are very pleased to have now launched this product and will leverage the investments we have made and the experience we have gained through this process to develop a range of respiratory and other complex treatment options for patients and healthcare providers, helping us to continue to put better health, within reach, every day.”<\/p>\n

\n Enquiries\u00a0<\/b>\n <\/p>\n

\n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b>\n <\/p>\n

\n\n\n\n\n\n
\n

\n
\n Hikma Pharmaceuticals PLC<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n<\/tr>\n
\n

\n Susan Ringdal<\/span>\n <\/p>\n

\n EVP, Strategic Planning and Global Affairs<\/span>\n <\/p>\n<\/td>\n

\n

\n +44 (0)20 7399 2760\/ +44 7776 477050<\/span>\n <\/p>\n

\n
\n uk-investors@hikma.uk.com<\/a>
\n <\/span>\n <\/p>\n

\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

\n Steve Weiss<\/span>\n <\/p>\n

\n David Belian<\/span>\n <\/p>\n

\n US Communications and Public Affairs\u00a0 <\/span>\n <\/p>\n<\/td>\n

\n

\n +1 732 720 2830\/ +1 732 788 8279<\/span>\n <\/p>\n

\n +1 732 720 2814\/+1 848 254 4875<\/span>\n <\/p>\n

\n
\n uscommunications@hikma.com<\/a>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n\n\n\n\n
\n

\n
\n Teneo (Press):\u00a0\u00a0<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n<\/tr>\n
\n

\n Charles Armitstead \/ Camilla Cunningham\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n +44 (0)7703 330 269\/ +44 (0)7464 982\u00a0426<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n About Hikma
<\/b>(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-\/stable S&P, BBB-\/stable Fitch and Ba1\/stable Moody’s)<\/p>\n

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States<\/span> (US), the Middle East<\/span> and North Africa<\/span> (MENA) and Europe<\/span>, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people’s lives. We’re committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit:\u00a0www.hikma.com<\/a><\/p>\n

\n Important Safety Information for <\/b>
\n Fluticasone Propionate and Salmeterol Inhalation Powder USP, <\/b>
\n 100mcg\/50mcg, 250mcg\/50mcg<\/b>
\n : <\/b>\n <\/p>\n

\n Contraindications
<\/b>The use of fluticasone propionate and salmeterol inhalation powder is contraindicated in the following conditions:<\/p>\n